Literature DB >> 15338485

Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset.

Sogol Amjadi1, Sogol Amjadi-Begvand, Dinesh Khanna, Grace S Park, Ken J Bulpitt, Weng Kee Wong, Harold E Paulus.   

Abstract

OBJECTIVE: A "window of therapeutic opportunity" has been hypothesized to be present in early rheumatoid arthritis (RA). To determine the date of this window, we must know the symptom-onset date of the RA. Patients participating in an observational study of early aggressive rheumatoid factor (RF) positive RA were evaluated to assess the accuracy of their recall of symptom-onset date by comparing the onset date they reported at the first visit with that reported on subsequent 6-monthly questionnaires.
METHODS: One hundred eighty-six patients with early RA (at entry: median disease duration 5.8 mo, mean RF 413.8 +/- 630.7 IU/ml, 20.6 +/- 10.9 swollen and 23.7 +/- 13.4 tender joints) completed a self-reported mailed questionnaire every 6 months for up to 5 years. As a part of each questionnaire, patients were asked to recall their RA symptom-onset date. These dates were then compared to the dates reported on the initial questionnaire.
RESULTS: Thirteen months after symptom onset (i.e., about 6 mo after study entry) 61% of patients recalled the symptom-onset date (within 1 mo) that they had reported at baseline; the proportion decreased to 39% at 31 months and 25% after 70 months. During this period, the proportion overestimating RA duration remained about 20%, but the proportion underestimating it increased from 23% at 13 months to 39% at 31 months, and to 50% after 56 months. Patients with longer disease duration, less disease activity, and higher pain levels tended to be less accurate.
CONCLUSION: Accuracy of recall of RA symptom-onset date by patients tends to decline over a period of 5 years. This should be taken into consideration when enrolling patients, when interpreting the findings of early RA clinical trials, and when attempting to ascertain the presence of a window of therapeutic opportunity.

Entities:  

Mesh:

Year:  2004        PMID: 15338485

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis.

Authors:  M Kristen Demoruelle; Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

2.  Examining radiographic outcomes over time.

Authors:  Grace S Park; Weng Kee Wong; Dinesh Khanna; Richard H Gold; Harold E Paulus
Journal:  Rheumatol Int       Date:  2013-10-29       Impact factor: 2.631

3.  The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.

Authors:  Kevin D Deane; Colin I O'Donnell; Wolfgang Hueber; Darcy S Majka; Ann A Lazar; Lezlie A Derber; William R Gilliland; Jess D Edison; Jill M Norris; William H Robinson; V Michael Holers
Journal:  Arthritis Rheum       Date:  2010-11

4.  MR imaging of atlantoaxial joint in early rheumatoid arthritis.

Authors:  N Magarelli; F Simone; R Amelia; A Leone; S Bosello; G D'Antona; A Zoli; G Ferraccioli; L Bonomo
Journal:  Radiol Med       Date:  2010-07-31       Impact factor: 3.469

5.  Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis.

Authors:  Mi Ryoung Seo; Hae Lim Baek; Hyun Hwa Yoon; Hee Jung Ryu; Hyo-Jin Choi; Han Joo Baek; Kwang-Pil Ko
Journal:  Clin Rheumatol       Date:  2014-09-05       Impact factor: 2.980

6.  Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.

Authors:  Haoling H Weng; Veena K Ranganath; Dinesh Khanna; Myungshin Oh; Daniel E Furst; Grace S Park; David A Elashoff; John T Sharp; Richard H Gold; James B Peter; Harold E Paulus
Journal:  J Rheumatol       Date:  2010-01-28       Impact factor: 4.666

7.  Early rheumatoid arthritis-do we really know what it means? Consistency and distribution of MRI findings according to different definitions for early rheumatoid arthritis.

Authors:  Iris Eshed; Eugen Feist; Christian E Althoff; Marina Backhaus; Gerd R Burmester; Bernd Hamm; Kay-Geert A Hermann
Journal:  Clin Rheumatol       Date:  2010-12-15       Impact factor: 2.980

8.  Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.

Authors:  Veena K Ranganath; Jeonglim Yoon; Dinesh Khanna; Grace S Park; Daniel E Furst; David A Elashoff; Damini Jawaheer; John T Sharp; Richard H Gold; Edward C Keystone; Harold E Paulus
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

9.  Disease progression in women with X-linked adrenoleukodystrophy is slow.

Authors:  Irene C Huffnagel; Marcel G W Dijkgraaf; Georges E Janssens; Michel van Weeghel; Björn M van Geel; Bwee Tien Poll-The; Stephan Kemp; Marc Engelen
Journal:  Orphanet J Rare Dis       Date:  2019-02-07       Impact factor: 4.123

10.  Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study.

Authors:  N Adib; K Hyrich; J Thornton; M Lunt; J Davidson; J Gardner-Medwin; H Foster; E Baildam; L Wedderburn; W Thomson
Journal:  Rheumatology (Oxford)       Date:  2008-04-16       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.